Table 1 Characteristics of included studies
Author | Publication year | Study years | Location | Study type | Bacteria | Carbapenemase | Carbapenem phenotype | Carbapenem MIC (mg/L) | Colistin MIC (mg/L) | Tigecycline MIC (mg/L) | Setting | Infection type | Polymyxin | Time-point | Number of patients | Dosage |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aslan | 2022 | 2014–2018 | Turkey | retrospective | KP | blaOXA−48, blaNDM, blaVIM | R | NA | NA | NA | Mix | BSI | colistin | 30 day | 53 | NA |
Boszczowski | 2019 | 2010–2013 | Brazil | retrospective | KP | blaKPC | R | NA | > 2 | NA | Mix | BSI | colistin | 30 day | 5 | NA |
Daikos | 2014 | 2009–2010 | Greece | retrospective | KP | blaKPC, blaVIM | R | > 8 | NA | NA | Mix | BSI | colistin | 28 day | 89 | 9 million IU colistin: 2–3 daily 100 to 200 mg tigecycline: 2 daily. 1 g imipenem and 1 g meropenem 3 daily |
Papadimitriou-Olivgeris | 2021 | 2010–2019 | Greece | retrospective | KP | blaKPC, blaVIM, blaNDM | R | NA | > 2 | > 2 | ICU | BSI | colistin | 30 day | 23 | NA |
Tumbarello | 2012 | 2010–2011 | Italy | retrospective | KP | blaKPC | R | ≥ 2 | ≤ 2 | ≤ 2 | Mix | BSI | colistin | 30 day | 64 | 6–9 million IU colistin: 2–3 daily 100-200 mg/day tigecycline. 2 g meropenem 3 daily |
Zarkotou | 2011 | 2008–2010 | Greece | retrospective | KP | blaKPC | R | > 1 | ≤ 2 | ≤ 2 | ICU | BSI | colistin | 14 day | 22 | NA |